Loading clinical trials...
Loading clinical trials...
An Open-label, Single Arm Study, Evaluating the Immunogenicity and Safety of HEPLISAV-B® in Adults With End-Stage Renal Disease (ESRD) Undergoing Hemodialysis
Conditions
Interventions
HEPLISAV-B®
Locations
20
United States
DaVita Clinical Research or Affiliate
Bloomfield, Connecticut, United States
DaVita Clinical Research or Affiliate
Middlebury, Connecticut, United States
DaVita Clinical Research or Affiliate
Hollywood, Florida, United States
DaVita Clinical Research or Affiliate
Ocala, Florida, United States
DaVita Clinical Research or Affiliate
Tampa, Florida, United States
DaVita Clinical Research or Affiliate
Winter Park, Florida, United States
Start Date
April 22, 2019
Primary Completion Date
October 23, 2020
Completion Date
September 15, 2021
Last Updated
August 9, 2024
Lead Sponsor
Dynavax Technologies Corporation
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions